Hussein Tawbi, Professor at The University of Texas MD Anderson Cancer Center shared on X:
“It was a true pleasure to chat with Bianna Golodryga and Ezekiel Emanuel on CNN International the potential impact of the recent results from the Moderna and Merck P3 trial with mRNA-based vaccine in patients with high risk melanoma.
Much can be built on this platform to improve the outcomes of patients with cancer.
You can also read: Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
